Danaher Corporation $DHR Shares Sold by FineMark National Bank & Trust

FineMark National Bank & Trust reduced its position in shares of Danaher Corporation (NYSE:DHR) by 0.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,818 shares of the conglomerate’s stock after selling 352 shares during the period. FineMark National Bank & Trust’s holdings in Danaher were worth $15,175,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC acquired a new position in Danaher in the 1st quarter valued at about $833,941,000. Generation Investment Management LLP boosted its stake in shares of Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the period. Invesco Ltd. grew its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Primecap Management Co. CA increased its stake in Danaher by 924.2% during the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after buying an additional 1,118,318 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after buying an additional 1,072,617 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 2.4%

NYSE:DHR opened at $225.75 on Wednesday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The stock has a market cap of $159.46 billion, a P/E ratio of 46.55, a P/E/G ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a 50-day simple moving average of $206.70 and a 200-day simple moving average of $201.47.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.71 earnings per share. As a group, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 29,728 shares of company stock worth $6,448,990 in the last ninety days. 11.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have commented on DHR. Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday, October 8th. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Finally, Bank of America lowered their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.